MedTrace Logo

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00716534 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2013-04-29

No results posted yet for this study

Summary

This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.

Conditions

  • Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

ABT-869

12.5 mg ABT-869

DRUG

Placebo for ABT-869

Placebo Comparator (12.5 mg or 7.5 mg)

DRUG

ABT-869

7.5 mg ABT-869

DRUG

Carboplatin

Carboplatin (AUC 6 mg/mL/min)

DRUG

Paclitaxel

Paclitaxel (200 mg/m2)

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Justin L. Ricker, MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States
  • Australia
  • Brazil
  • Czechia
  • Russia
  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00716534 on ClinicalTrials.gov